What Is "The Next $52 Billion Startup" Stock?

Welcome to my review of Michael A. Robinson’s presentation on The Next $52 Billion Startup.

Michael claims to have unearthed a startup that has found a way of fashioning CBD (from cannabis) into a drug that can cure four inflammatory diseases effectively and with no side effects.

But is the company good enough to spark genuine interest from an investment perspective?

In this review, I provide you with a concise account of what Michael discusses in the presentation from a business perspective (if you are interested in the esoteric ways in which the drugs work, you can check out the presentation).

I also share my opinion on whether the presentation is legit and trustworthy and offer my verdict on the feasibility of Michael’s propositions.

Before we start…

Looking for a real way to make money online? Check out my no.1 recommendation below.

It’s made us over $124,000 in the last 3 months alone:

Go here to see my no.1 recommendation for making money online

(This is free)

Go Here To See My No.1 Recommendation!

Table of Contents

What is The Next $52 Billion Startup?

The Next $52 Billion Startup is a presentation by Michael A. Robinson (interviewed by Mike Ward).

Although I have encountered much of Michael’s work in a technology investment sense, he is also a cannabis venture capital expert. He is a member of the National Institute of Cannabis Investors (NICI).

He claims to have unearthed a cannabis startup that has the potential to become a $52 billion company in the coming years. If you invest in it, you may earn a windfall from a small investment if everything goes according to plan.

It all has to do with a medical breakthrough involving two potential cures for a bunch of deadly diseases that we haven’t found effective cures for.

The company in question is called Emerald Health Pharmaceuticals. Its scientists have been working on two drugs made from Cannabinoids (found naturally in Cannabis).

For the first drug, they took natural CBD (Cannabidiol) and improved it to create a synthetic derivative that will be used to treat inflammatory diseases, and for the second drug, they did the same to natural CBG (Cannabigerol).

The two new treatments will be so effective, they will not cause undesirable side effects.

Emerald Health Pharmaceuticals has patents for its artificial molecules and with FDA approval, it could be a monopoly in an untapped multi-billion market.

For these reasons, Michael wants you to invest in the company to make money when (if) it becomes successful.

Who is Michael A. Robinson?

Michael A. Robinson is a technology investment expert. He has been working at Silicon Valley for 35 years and is considered one of the top financial analysts in the tech industry. He was behind the presentation about The “Dark Burst” Solar Technology Device.

He gives financial advice to a group of followers through his newsletter subscriptions. For instance, he publishes the Nova-X Report, Radical Technology Profits, and Strategic Tech Investor via Money Map Press.

In addition to editing newsletters, he is a consultant for Silicon Valley venture capital firms. The role suits him because as an insider, he has access to many pioneering CEOs, inventors, and industry insiders.

He has been a regular guest panelist for Fox Business and CNBC.

How does The Next $52 Billion Startup work?

The opportunity that Michael presents here is not a public company that you can trade in the stock market. It is a private company, which means investing in it is not as straightforward.

One problem with investing in startups is that you have to be an accredited investor. Fortunately, Emerald is conducting Regulation A+ funding rounds, which allows investors who are not accredited to partake.

If you would like to receive the details you’d need to invest in Emerald Health Pharmaceuticals, you have to subscribe to a new research service Michael is starting called Cannabis Venture Syndicate.

A one-year subscription goes for $1,950.

If you become a member, not only will he send you details about Emeralds, he will provide you with between five to six other new private investment opportunities in one year.

He will also send you:

A short guide on private investment. He calls it the Private Investing Primer.
Pitch Decks (videos) from CEOs of startups seeking new investors. They explain what their companies do, who are on their team, and why you should invest in them.
A Due Diligence Package. It is a report that presents you with an analysis of a target company’s financials as well as its competition. It is also accompanied by a Deal Memo and a Terms Sheet to enable you to decide whether an investment is good enough.
The Cannabis Venture Syndicate deal record. It is like his model portfolio.

You also get invited to The Cannabis Venture Mastermind where you can create online forums with other members to share ideas.

Merits of The Next $52 Billion Startup

If everything goes according to plan – the FDA approves the drugs and they hit the market – you may earn a fortune from a small investment.
Two exit options earn you massive payoffs: either when the company is acquired or when it goes public.

Demerits of The Next $52 Billion Startup

The business is still unproven; it may fail to take off as Michael expects it to thus leading to massive losses.
Only a few people can subscribe to Cannabis Venture Syndicate. The number of new members is restricted.

Is The Next $52 Billion Startup legit?

I think The Next $52 Billion Startup presentation is legit because Emerald Health Pharmaceuticals has been conducting clinical trials on rodents and the drugs have proven to be effective. The results have even been published on notable medical journals like Nature’s Scientific Reports.

They are set to conduct human trials as they vie for FDA approval, which they look likely to get. If they reach that stage, the example set by Biogen and Corbus – which both have developed treatments for the illnesses Emerald is targeting – shows that they may be successful.

My Final Word on The Next $52 Billion Startup

The Next $52 Billion Startup is a presentation that is designed to pique your interest in private investments in the Cannabis industry. The industry has garnered a lot of attention over the past few years thanks to a relaxation of many States’ laws that illegalized medical and recreational Marijuana.

But before you get carried away, bear in mind that many other states are either in the process of revising their laws or have no desire to do so, for now.

That being said, the states that have so far descheduled Marijuana use medically and/or recreationally have been enough to spark genuine interest from investors.

The National Institute for Cannabis Investors was created to help investors make more informed moves in the fledgling market.

Ultimately, you will be better off subscribing to Michael’s service if you are still new to the industry.

Don’t leave yet…

Looking for a real way to make money online? Check out my no.1 recommendation below.

It’s made us over $124,000 in the last 3 months alone:

Go here to see my no.1 recommendation for making money online

(This is free)

Go Here To See My No.1 Recommendation!